BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Career Advice

  9 Common Interview Mistakes That Could Cost You the Job

  The job interview is a delicate kind of “dance” between job seeker and employer. Therefore, to succeed you must avoid these common interview mistakes.

  June 6, 2018

   · 

  5 min read

   · 

  Editorial Staff
• 

  Business

  Senti Biosciences Brings on Curt Herberts to Help Build New Partnerships

  South San Francisco-based Senti Biosciences is getting a new Chief Financial Officer and Chief Business Officer. Former Sangamo Therapeutics Senior Vice President and Chief Business Officer Curt Herberts will join Senti later this month.

  June 6, 2018

   · 

  1 min read

   · 

  Don McCormick
• 

  Drug Development

  What’s the Deal with Longevity Company Unity Biotechnology and its $700 Million Valuation?

  Unity Biotechnology has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell.

  June 6, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  6 Months After Pfizer Cuts Neuroscience Development, Adds $600 Million to Venture Arm with 25% Slated for Neuroscience

  Pfizer is now throwing an additional $600 million into its venture capital fund, with a quarter of it earmarked for neuroscience research investments.

  June 6, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Cancer Research, Medical Records Targeted by Amazon Mystery Initiative

  The secret group within Amazon working on a series of bold projects is starting to become a little less secret.

  June 6, 2018

   · 

  2 min read

   · 

  Don McCormick
• 

  Business

  Two of Allergan’s Biggest Investors Call for Management Split

  Appaloosa Management’s David Tepper and Senator Investment Group’s Douglas Silverman sent a letter to Allergan’s board of directors yesterday asking—or demanding—that the company split the roles of chief executive officer and chairman.

  June 6, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Axovant Licenses Gene Therapy for Parkinson’s Disease from Oxford BioMedica

  Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.

  June 6, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Rob Reiner Kicks Off Day 3 of BIO Convention

  Actor, director and advocate Rob Reiner opened the third day of the 2018 BIO International Convention.

  June 6, 2018

   · 

  2 min read

   · 

  Don McCormick
• 

  Genetown

  Biogen Pays Alkermes $50 Million Milestone for MS Drug

  Alkermes, received a $50 million milestone payment from Biogen. The payment occurred after Biogen reviewed preliminary gastrointestinal tolerability data from an ongoing Phase III clinical trial for MS.

  June 6, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Biotech Beach

  Metacrine Closes $65 Million Series C Round

  Metracrine, based in San Diego, completed a Series C financing round worth $65 million.

  June 6, 2018

   · 

  3 min read

   · 

  Mark Terry